St Jude Medical has presented new data that supports improved outcomes and cost-effectiveness of the CardioMEMS HF System for the management of Class III heart failure patients at the Heart Rhythm Society’s (HRS) 36th Annual Scientific Session in Boston, US.
The presentation showed that pulmonary artery (PA) pressure management in heart failure patients with cardiac resynchronisation therapy (CRT) or implantable cardioverter defibrillator devices (ICDs) significantly reduced hospitalisations and mortality above and beyond background guideline-directed medical therapy.
Ohio State University Wexner Medical Center cardiovascular medicine chief Dr William Abraham said: "Even in patients being managed in accordance with American College of Cardiology and American Heart Association guidelines for medical management and device therapy, we saw a decrease in all-cause hospitalisations and mortality for Class III heart failure patients when we added pulmonary artery pressure monitoring with the CardioMEMS HF System.
"These data show a 43% reduction in heart failure hospitalisations and 53% reduction in mortality, which demonstrates the added value of PA pressure monitoring in an already well-managed patient population."
St Jude Medical medical director Dr Philip Adamson said: "We are encouraged by these analyses indicating that the CardioMEMS HF System is a cost-effective solution."
Conducted at the University of Pennsylvania, the CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Patients (CHAMPION) trial found that heart failure hospitalisations were significantly low when clinicians used PA pressures from the CardioMEMS HF System, rather than relying on clinical signs and symptoms.
The findings confirm that early intervention through the identification of increased PA pressure weeks prior to clinical signs and symptoms, reduce HF hospitalisations.
A new economic analysis of data displayed an incremental cost-effectiveness ratio based on all-cause comprehensive management of heart failure patients of $30,167 per quality-adjusted life year gained when patients were managed by PA pressure monitoring.
Data presented during American Heart Association (AHA) 2014 also showed a 58% reduction in 30-day all-cause re-admissions through usage of the CardioMEMS HF System.
The CardioMEMS System uses a miniaturised, wireless monitoring sensor that is implanted in the PA during a minimally invasive procedure to directly measure PA pressure.
The system also helps patients transfer data from their homes to their healthcare providers, who manage appropriate medication changes to reduce the likelihood of hospitalisation.
Image: Data from the CHAMPION trial found that heart failure hospitalisations were significantly lowered when clinicians used PA pressures from the CardioMEMS HF system. Photo: courtesy of Business Wire.